Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
7.23M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
1.8M
-
Shares change
-
-283K
-
Total reported value, excl. options
-
$13.9M
-
Value change
-
-$1.94M
-
Number of buys
-
9
-
Number of sells
-
-14
-
Price
-
$7.72
Significant Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q2 2025
40 filings reported holding ATRA - Atara Biotherapeutics, Inc. - Common Stock as of Q2 2025.
Atara Biotherapeutics, Inc. - Common Stock (ATRA) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.8M shares
of 7.23M outstanding shares and own 24.94% of the company stock.
Largest 10 shareholders include EcoR1 Capital, LLC (573K shares), Redmile Group, LLC (442K shares), VANGUARD GROUP INC (191K shares), Vestal Point Capital, LP (94.1K shares), STALEY CAPITAL ADVISERS INC (75K shares), BlackRock, Inc. (70.8K shares), ACADIAN ASSET MANAGEMENT LLC (65.2K shares), GEODE CAPITAL MANAGEMENT, LLC (60.1K shares), MARSHALL WACE, LLP (42.4K shares), and STATE STREET CORP (25.3K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.